{
    "clinical_study": {
        "@rank": "33511", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Increasing of dose period : Duration is 6 weeks. Dose is 1 tablet to maximum 6 tablets Maintained period : Duration is 4 weeks. Dose is 2 tablets  to maximum 6 tablets Tapering dose period : The duration of the tapering phase for each subject will depend on investigator's discretion. Maximum 4 weeks"
            }, 
            {
                "arm_group_label": "SME3110 (fluvoxamine maleate)", 
                "arm_group_type": "Experimental", 
                "description": "Increasing of dose period : Duration is 6 weeks. Dose is 25mg/day to maximum 150mg/day Maintained period : Duration is 4 weeks. Dose is 50mg/day to maximum 150mg/day Tapering dose period : The duration of the tapering phase for each subject will depend on investigator's discretion. Maximum 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective in 1st phase of this randomized study is to evaluate the efficacy of SME3110\n      compared to placebo on change in total score of Japanese version of the Children's\n      Yale-Brown Obsessive Compulsive Scale 10-item for children from baseline to the last\n      observation visit in pediatric/adolescent Obsessive Compulsive Disorder subjects in\n      short-term (10 weeks) in double blind period.  The safety of SME3110 compared to placebo is\n      also evaluated.\n\n      The objective in 2nd phase of the study is to evaluate the long-term safety and efficacy of\n      SME3110 in pediatric/adolescent Obsessive Compulsive Disorder subjects."
        }, 
        "brief_title": "A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obsessive Compulsive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "The 1st phase will be conducted in a randomized, placebo-controlled, double-blind manner to\n      evaluate the efficacy of SME3110 on change from baseline to the last observation visit in\n      Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total\n      score.  Eligible patients will be allocated in SME3110 group or placebo group with 1:1 ratio\n      using the experience of fluvoxamine treatment and age as the stratification factor (dynamic\n      allocation).  The 1st phase consists of 5 periods; screening period of 1-2 weeks, forced\n      titration dose period of 2 weeks, dose adjustment period of 4 weeks, maintained dose period\n      of 4 weeks, and tapering dose period of 0-4 weeks.\n\n      The 2nd phase will be conducted in an open-label manner in patients who completed the 1st\n      phase to evaluate long-term safety of SME3110.  The 2nd phase consists of 3 periods; forced\n      titration dose period of 2 week, flexible dose period of 50 weeks, and tapering dose period\n      of 0-4 weeks.  After the last dose of study drug (including tapering dose period) or the\n      early termination visit, subjects will be followed up to 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has at least 16 scores in Japanese version of the Children's Yale-Brown\n             Obsessive Compulsive Scale 10-item total score and at least 5 scores in Obsession sub\n             total score and in Compulsion sub-total score respectively at the Screening period\n             and Baseline.\n\n          2. Subject showed less than 25% reduction in Japanese version of the Children's\n             Yale-Brown Obsessive Compulsive Scale 10-item total score at Baseline compared to the\n             score at the Screening period (Total score at Baseline \u2265 Total score at Screening \u0445\n             0.75).\n\n          3. Subject has Obsessive compulsive disorder symptoms at least for 2 months prior to\n             informed consent.\n\n          4. Body weight: \u2265 standard weight - 2 standard deviation based on the standard weight\n             for each age in the School Health Statistical Survey.\n\n          5. Subjects with parent or legal guardian who have received explanation about the\n             purpose, procedure and meaning of the study sufficiently and is willing to give\n             written informed consent for the subject. (if possible, written informed assent will\n             be obtained from the subject).\n\n        Exclusion Criteria:\n\n          1. Subject has only trichotillomania (Diagnostic and Statistical manual of Mental\n             Disorders Forth Edition Text Revision: 312.39) or nail-biting as his/her compulsive\n             symptoms.\n\n          2. Subject has Tourette's disorder (Diagnostic and Statistical manual of Mental\n             Disorders Forth Edition Text Revision: 307.23).  However, the simple motor tic is not\n             excluded.\n\n          3. Subject is diagnosed as the following psychiatric disorders.\n\n               -  Schizophrenia (Diagnostic and Statistical manual of Mental Disorders Forth\n                  Edition Text Revision: 295.xx) and other psychotic disorders (Diagnostic and\n                  Statistical manual of Mental Disorders Forth Edition Text Revision: 295.40\n                  [schizophreniform disorder], 295.70 [schizoaffective disorder], 297.1\n                  [delusional disorder], 298.8 [brief psychotic disorder], 297.3 [shared psychotic\n                  disorder], 293.xx [psychotic disorder due to\u2026 {indicate the general medical\n                  condition}], substance induced psychotic disorder, 298.9 [psychotic disorder not\n                  otherwise specified]).\n\n               -  Depressive disorders Diagnostic and Statistical manual of Mental Disorders Forth\n                  Edition Text Revision: 296.xx [major depressive disorder], 296.2x [single\n                  episode], 296.3x [recurrent], 300.4 [dysthymic disorder], 311 [depressive\n                  disorder not otherwise specified]).\n\n               -  Bipolar disorders (Diagnostic and Statistical manual of Mental Disorders Forth\n                  Edition Text Revision: 296.xx [bipolar I disorder], 296.0x [single manic\n                  episode], 296.40 [most recent episode hypomanic], 296.4x [most recent episode\n                  manic], 296.6x [most recent episode mixed], 296.5x [most recent episode\n                  depressed], 296.7 [most recent episode unspecified], 296.89 [bipolar II\n                  disorder], 301.13 [cyclothymic disorder], 296.80 [bipolar disorder not otherwise\n                  specified]).\n\n               -  Mental retardation (Diagnostic and Statistical manual of Mental Disorders Forth\n                  Edition Text Revision: 317 [mild mental retardation], 318.0 [moderate mental\n                  retardation], 318.1 [severe mental retardation], 318.2 [profound mental\n                  retardation], 319 [mental retardation, severity unspecified]).\n\n               -  Eating disorders (Diagnostic and Statistical manual of Mental Disorders Forth\n                  Edition Text Revision: 307.1 [anorexia nervosa], 307.51 [bulimia nervosa],\n                  307.50 [eating disorder not otherwise specified]).\n\n               -  Attention-deficit/hyperactivity disorder (Diagnostic and Statistical manual of\n                  Mental Disorders Forth Edition Text Revision: 314.xx) and attention\n                  deficit/hyperactivity disorder not otherwise specified (Diagnostic and\n                  Statistical manual of Mental Disorders Forth Edition Text Revision: 314.9).\n\n               -  Obsessive compulsive personality disorder (Diagnostic and Statistical manual of\n                  Mental Disorders Forth Edition Text Revision: 301.4).\n\n               -  Other patients with clinical neurological disorder.\n\n          4. Subject who diagnose Major Depressive Disorder by The Mini-International\n             Neuropsychiatric Interview for Children and Adolescents (A) at the Screening period.\n\n          5. Subject has been treated with fluvoxamine within 2 months prior to informed consent.\n             Except for the those who the fluvoxamine dose is not stable and the administration\n             period of fluvoxamine is within 6 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933919", 
            "org_study_id": "M13-970"
        }, 
        "intervention": [
            {
                "arm_group_label": "SME3110 (fluvoxamine maleate)", 
                "intervention_name": "fluvoxamine maleate", 
                "intervention_type": "Drug", 
                "other_name": "SME3110 Luvox Depromel"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Maleic acid", 
                "Fluvoxamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adolescent Subjects", 
            "Pediatric Subjects", 
            "Obsessive Compulsive Disorder"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Eiheiji-cho", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105819"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105819", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuchu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112837"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112837", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112839"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112839", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105823"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105823", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 126799"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126799", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105820"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105820", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105826"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105826", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105818"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105818", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105821"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105821", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ichikawa-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105822"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105822", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112835"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112835", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112842"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112842", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moriguchi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105816"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105816", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112836"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112836", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nara", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105817"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105817", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oita-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 126801"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126801", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112841"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112841", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 126798"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126798", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saga", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105825"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105825", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105824"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105824", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakai-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 127032"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127032", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakai-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 127031"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127031", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 126797"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126797", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105815"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105815", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112840"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112840", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112838"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112838", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 112843"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 112843", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 126800"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126800", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder", 
        "overall_contact": {
            "email": "AbbVie_JPN_info_clingov@abbvie.com", 
            "last_name": "AbbVie  AbbVie GK Clinical Trials Registration Desk"
        }, 
        "overall_contact_backup": {
            "email": "masafumi.oshita@abbvie.com", 
            "last_name": "Masafumi  Oshita, PhD", 
            "phone": "+81-3-4577-9435"
        }, 
        "overall_official": {
            "affiliation": "AbbVie GK", 
            "last_name": "Susumu  Matsuki, BS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 10 (1st phase)"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 10 (1st phase)"
            }, 
            {
                "measure": "Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score.", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 52 (2nd phase)"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52 (2nd phase)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Baseline factors are an experience of treatment with fluvoxamine in the past, age and gender.", 
                "measure": "Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score stratified by each factor", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 10 (1st phase)"
            }, 
            {
                "measure": "Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and subscore at each measurement", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 10 (1st phase)"
            }, 
            {
                "measure": "Clinical Global Impression Improvement", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 10 (1st phase)"
            }, 
            {
                "measure": "The proportion of subject with a \u2265 25% decrease from baseline in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 10 (1st phase)"
            }, 
            {
                "measure": "The proportion of subject with a \u2265 35% decrease from baseline in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 10 (1st phase)"
            }, 
            {
                "measure": "The change from baseline to each post-baseline measurement in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 52 (2nd phase)"
            }, 
            {
                "measure": "Clinical Global Impression", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 52 (2nd phase)"
            }, 
            {
                "measure": "Change of Laboratory test result, Body weight, Blood pressure and Pulse rate", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 10 (1st phase)"
            }, 
            {
                "measure": "Change of Laboratory test result, Body weight, Blood pressure and Pulse rate, and Electrocardiography", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 52 (2nd phase)"
            }, 
            {
                "description": "Withdrawn syndrome includes headache, nausea, dizziness, anxiety feelings, insomnia, loss of concentration", 
                "measure": "A change in Frequency of Withdrawn Syndrome", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 10 to Week 14 (1st Phase)"
            }, 
            {
                "description": "Withdrawn syndrome includes headache, nausea, dizziness, anxiety feelings, insomnia, loss of concentration", 
                "measure": "A change in Frequency of Withdrawn Syndrome", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 52 to Week 56 (2nd Phase)"
            }, 
            {
                "measure": "The Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and sub-score", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 10 (1st phase)"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Meiji Seika Pharma Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}